-
公开(公告)号:US11279682B2
公开(公告)日:2022-03-22
申请号:US16294647
申请日:2019-03-06
Applicant: H. Lundbeck A/S
Inventor: Heidi Lopez de Diego , Kim Lasse Christensen , Rene Holm , Jens Kateb
IPC: C07D295/096 , C07D207/28
Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.
-
公开(公告)号:US09353073B2
公开(公告)日:2016-05-31
申请号:US14767350
申请日:2014-02-20
Applicant: H. Lundbeck A/S
Inventor: Thomas Ruhland , Kim Lasse Christensen
IPC: C07D295/096 , C07F15/02
CPC classification number: C07D295/096 , C07F15/02
Abstract: A process for the manufacture of vortioxetine is provided in which a compound of formula I, formula I is reacted with optionally substituted piperazine and 2,4-dimethylthiophenol(ate) followed by de-cmplexation.
Abstract translation: 提供了一种制备伏妥托汀的方法,其中式I式I化合物与任选取代的哌嗪和2,4-二甲基苯硫酚(ate)反应,随后进行去络合。
-
3.Process for the Manufacture of 1-[2-(2,4-Dimethyl-Phenylsulfanyl)-Phenyl]-Piperazine 有权
Title translation: 1- [2-(2,4-二甲基 - 苯基硫基) - 苯基] - 哌嗪的制备方法公开(公告)号:US20140343287A1
公开(公告)日:2014-11-20
申请号:US14370322
申请日:2012-12-20
Applicant: H. Lundbeck A/S
Inventor: Kim Lasse Christensen
IPC: C07D295/096
CPC classification number: C07D295/096 , Y02P20/55
Abstract: A process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine and pharmaceutically acceptable salts is disclosed that involves reacting compounds of formula II, III, IV under Pd catalysis and in presence of phosphine ligands to give Compound I.
Abstract translation: 公开了制备1- [2-(2,4-二甲基 - 苯硫基) - 苯基] - 哌嗪及其药学上可接受的盐的方法,其涉及在Pd催化下和在膦存在下使式II,III,IV的化合物反应 配体给予化合物I.
-
公开(公告)号:US10287261B2
公开(公告)日:2019-05-14
申请号:US15152902
申请日:2016-05-12
Applicant: H. Lundbeck A/S
Inventor: Heidi Lopez de Diego , Kim Lasse Christensen , Rene Holm , Jens Kateb
IPC: C07D295/096 , A61P25/00 , A61K31/495 , C07D207/28
Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.
-
公开(公告)号:US20190210987A1
公开(公告)日:2019-07-11
申请号:US16294647
申请日:2019-03-06
Applicant: H. Lundbeck A/S
Inventor: Heidi Lopez de Diego , Kim Lasse Christensen , Rene Holm , Jens Kateb
IPC: C07D295/096 , C07D207/28
CPC classification number: C07D295/096 , C07D207/28
Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt
-
6.Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine 有权
Title translation: 1- [2-(2,4-二甲基 - 苯硫基) - 苯基] - 哌嗪的制备方法公开(公告)号:US09133144B2
公开(公告)日:2015-09-15
申请号:US14370322
申请日:2012-12-20
Applicant: H. Lundbeck A/S
Inventor: Kim Lasse Christensen
IPC: C07D295/04 , C07D295/096
CPC classification number: C07D295/096 , Y02P20/55
Abstract: A process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine and pharmaceutically acceptable salts is disclosed that involves reacting compounds of formula II, III, IV under Pd catalysis and in presence of phosphine ligands to give Compound I.
Abstract translation: 公开了制备1- [2-(2,4-二甲基 - 苯基硫基) - 苯基] - 哌嗪及其药学上可接受的盐的方法,其涉及在Pd催化下和膦存在下使式II,III,IV的化合物反应 配体给予化合物I.
-
公开(公告)号:US20160368884A1
公开(公告)日:2016-12-22
申请号:US15152902
申请日:2016-05-12
Applicant: H. Lundbeck A/S
Inventor: Heidi Lopez de Diego , Kim Lasse Christensen , Rene Holm , Jens Kateb
IPC: C07D295/096 , C07D207/28
CPC classification number: C07D295/096 , C07D207/28
Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.
Abstract translation: 本发明提供了含有所述盐的伏妥妥汀焦谷氨酸盐和药物组合物。
-
公开(公告)号:US20160009670A1
公开(公告)日:2016-01-14
申请号:US14767350
申请日:2014-02-20
Applicant: H. LUNDBECK A/S
Inventor: Thomas Ruhland , Kim Lasse Christensen
IPC: C07D295/096 , C07F15/02
CPC classification number: C07D295/096 , C07F15/02
Abstract: A process for the manufacture of vortioxetine is provided in which a compound of formula I, formula I is reacted with optionally substituted piperazine and 2,4-dimethylthiophenol(ate) followed by de-complexation.
Abstract translation: 提供了一种制备伏妥托汀的方法,其中式I式I化合物与任选取代的哌嗪和2,4-二甲基苯硫酚(ate)反应,随后脱络合。
-
-
-
-
-
-
-